GlassScriptPhysician profile
Gregory Lawrence Desanto
NPI 1639163819
$12,581.94
in general payments reported to CMS, 2019-2025
29 companies · $27.78 in 2025
The $27.78 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $961 · 2020: $197 · 2021: $9,429 · 2022: $770 · 2023: $686 · 2024: $511 · 2025: $27.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $699 · Travel and Lodging: $471 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $55.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $698.65 |
| Travel and Lodging | $471.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $55.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $9,134.85 | 2020-2021 | |
| Applied Medical Resources Corporation | $961.27 | 2019-2023 | Gelpoint V-Path |
| Abbvie INC. | $440.30 | 2019-2024 | Lo Loestrin Fe, Liletta |
| Amgen INC. | $418.58 | 2019-2023 | Prolia, Evenity |
| Gynesonics, INC. | $264.78 | 2022 | |
| Hologic Sales and Service, LLC | $231.00 | 2019-2024 | Acessa Provu System, Myosure Tissue Removal Device, Novasure |
| Bayer Healthcare Pharmaceuticals INC. | $142.16 | 2019-2024 | |
| Minerva Surgical, INC | $134.60 | 2021-2024 | |
| Organon LLC | $90.84 | 2021-2023 | Nexplanon |
| Exeltis, USA INC. | $72.07 | 2019-2023 | Slynd |
| Aspira Women'S Health INC | $69.22 | 2019-2025 | Ova1 |
| Astellas Pharma US INC | $68.03 | 2023-2024 | Veozah |
| Millicent US INC | $68.00 | 2019-2024 | Femring, Intrarosa |
| Daiichi Sankyo INC. | $60.29 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $54.27 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $53.56 | 2024 | Paragard T 380a, Vaginal Speculum - Snowman/ Pederson Blade |
| Therapeuticsmd, INC. | $43.10 | 2020-2022 | |
| Allergan, INC. | $36.18 | 2019 | |
| Evofem Biosciences, INC. | $31.38 | 2021-2022 | |
| Pfizer INC. | $30.71 | 2019-2024 | |
| Covidien LP | $30.48 | 2019 | |
| Amag Pharmaceuticals, INC. | $30.01 | 2019 | |
| Scynexis, INC. | $26.66 | 2022 | |
| Mylan Pharmaceuticals INC. | $17.92 | 2021 | |
| Myovant Sciences INC. | $16.24 | 2021 | |
| Exact Sciences Corporation | $14.71 | 2025 | Cologuard Collection Kit |
| Mayne Pharma Commercial LLC | $14.55 | 2024 | |
| Becton, Dickinson and Company | $14.53 | 2022 | |
| Alfasigma USA, INC. | $11.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Desanto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.